Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Business Wire India Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU CUVITRU is Takeda’s First Subcutaneous Immunoglobulin Plasma…